Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 06/14/24 03:15:00 on US and Canada Markets.
2024-06-14 03:15:00 ET The biggest investment mistakes you make are likely to come from situations where you don't fully understand the asset you are buying. That's actually easy to do in the exchange-traded fund (ETF) space, because the logic behind many of the ETFs out there is complex an...
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress PR Newswire - Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA ® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML , inc...
2024-06-14 03:05:00 ET There's no getting around the impact of artificial intelligence (AI) in tech circles since early last year, and Broadcom (NASDAQ: AVGO) is a key player in the space. The company's semiconductors and data center infrastructure play a critical part in the AI...
2024-06-14 03:03:00 ET There are plenty of reasons to be pessimistic about the electric vehicle (EV) industry now, but that could also make it a perfect time to buy in while stock prices are depressed. To be fair, not every EV investment is going to pan out as many companies are in a cash c...
- Results from CLIMB-111, -121 and -131 accepted for oral presentation - - Data from these trials, with the longest follow-up of more than five years, demonstrate transformative, consistent and durable benefit of CASGEVY™ - - Safety profile consistent with busulfan condit...
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal ...
Patients in MagnetisMM-3 demonstrated a median overall survival (OS) of 24.6 months, with median progression-free survival (PFS) of 17.2 months Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (e...
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its optimized, closed and automated manufacturing process for its base-edited CD34+ hematopoietic ...
Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera Patients receiving rusfertide in the open-label extension of the REVIV...
– Analysis Shows Manufacturing of Yescarta in Second-Line Treatment of Relapsed/Refractory Large B-cell Lymphoma Can Help Reduce Time from Leukapheresis to Infusion vs. Third-Line+ Treatment – – Data Builds on Previous Evidence on the Association Between Timely In...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
7.48%Change Percent:
Tandem Diabetes Care Inc. Company Name:
TNDM Stock Symbol:
NASDAQ Market:
tandemdiabetes.com Website: